Johnson & Johnson Kick-Starts Suzhou Production
This article was originally published in PharmAsia News
Johnson & Johnson Medical has commenced operation at its Suzhou Industrial Park, starting off with orthopedic implants, which have been experiencing the fastest growth in the firm's portfolio. The first DePuy factory will make products related to artificial joint replacement and trauma care to fulfill 10-20 percent of the company's global output. With other localized products coming online, the Suzhou base is set to become J&J Medical's largest production facility in the next five years. There are plans to introduce minimally invasive surgical devices by the end of this year and cardiology products in 2009. China is experiencing huge domestic demand and growth for orthopedic implants; the market is expected to increase from 500 million yuan in 2007 to 2.1 billion yuan in 2015. (Click here for more - Chinese Language)
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.